[Recordati] Announcement regarding the drug price listing and launch date of myelofibrosis treatment 'Inrebic®'

This release is intended for members of the press and is not intended for medical information or promotional purposes.

Recordati Rare Diseases Japan Co., Ltd. (Headquarters: Tokyo, hereinafter "Recordati") announced today that the myelofibrosis treatment "Inrebic®" (generic name: fedratinib hydrochloride hydrate) has been listed on the drug price standard. In light of this, Recordati will launch Inrebic® on June 1 of this year.

Inrebic® is an oral kinase inhibitor targeting wild-type and activated mutant Janus kinase (JAK) 2. It has high selectivity and inhibitory activity against JAK2 and is expected to exhibit therapeutic effects by controlling the pathology of myelofibrosis.

Product Overview
Brand Name: Inrebic Capsules 100mg
Generic Name: Fedratinib hydrochloride hydrate
Indication: Myelofibrosis
Dosage and Administration: Typically, adults are administered 400 mg of fedratinib once daily orally. Dosage may be reduced appropriately based on the patient's condition.
Drug Price: Inrebic Capsules 100mg: 11,137.40 JPY per capsule
Date of Manufacturing and Marketing Approval: June 24, 2025 (Recordati succeeded the manufacturing and marketing approval from Bristol Myers Squibb K.K. in February 2026)
Date of Listing on Drug Price Standard: May 20, 2026
Scheduled Launch Date: June 1, 2026
Manufacturer and Distributor: Recordati Rare Diseases Japan Co., Ltd.
Distributor: Recordati Rare Diseases Japan Co., Ltd.

About Recordati
Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange (XMIL: REC), with a history originating as a family-run pharmacy in Northern Italy in the 1920s. The company has a unique structure capable of providing treatments across specialty care, primary care, and the rare disease area. It operates a fully integrated business from clinical development, active pharmaceutical ingredient and drug product manufacturing, commercialization, to out-licensing. The company operates in approximately 150 countries across EMEA (Europe, Middle East, and Africa), the Americas, and APAC (Asia Pacific) with approximately 4,700 employees. We believe that health is a fundamental right, not a privilege. Currently, our mission, "unlocking the full potential of life," aims to help people enjoy their lives to the fullest, whether addressing general health challenges or the rarest diseases.